EHA Unplugged

Get up to date with the EHA–ESMO guidelines on Human immunodeficiency virus (HIV)-associated Lymphomas. In this episode, Prof. Kai Hubel, a key author of the guidelines, explains the importance of having dedicated recommendations for patients with HIV-associated lymphomas. He begins by discussing the prevalence of lymphomas in people living with HIV, then highlights that the modern CART HIV treatment should be combined with the lymphoma treatments. This interview further provides practical guidance to navigate these detailed recommendations that cover key lymphoma subtypes including DLBCL, Burkitt lymphoma, plasmatic lymphoma, and more. Finally, Prof Hubel advocates for the inclusion of people living with HIV in lymphoma clinical trials to increase evidence base on HIV-associated lymphomas and improve the care for this specific patient populations. Link to the guideline: Human immunodeficiency virus‐associated Lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow‐up - Hübel - 2024 - HemaSphere - Wiley Online Library Guest:  Prof Kai Hübel Department of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Cologne, GermanyHost: Isabel Olivera Martinez, PhDLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.⁠⁠⁠⁠⁠⁠Provide Feedback⁠⁠⁠⁠⁠⁠Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.⁠⁠⁠⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠⁠⁠⁠Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: ⁠⁠⁠⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠⁠⁠⁠Facebook: ⁠⁠⁠⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠⁠⁠⁠LinkedIn: ⁠⁠⁠⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠⁠⁠⁠Email us: [email protected] to receive the EHA Educational Updates via ⁠⁠⁠⁠⁠⁠https://eha.news/subscribe⁠⁠⁠⁠⁠⁠

Join Meritxell Alberich Jordà, an EHA Board member and a principal investigator from Prague, as she shares her journey to becoming a recognised research scientist in hematology, and the role EHA has played along the way. Her lab studies hematopoietic and leukemic stem cells, focusing on how disruptions in transcriptional regulation and inflammatory signalling drive the development and persistence of acute myeloid leukemia.  Meri reflects on how her early research interests evolved over time, how key career decisions shaped the questions she pursues today, and what she finds most rewarding about leading a lab. Tune in to hear what she wishes she’d known at the very beginning of her journey. Guest: Associate Prof Meritxell Alberich JordàInstitute of Molecular Genetics of the Czech Academy of Sciences, Laboratory of Haematooncology Head, Prague, Czech Republic The Childhood Leukaemia Investigation Prague in the Department of Pediatric Haematology and Oncology, 2nd Faculty of Medicine, Charles University, University Hospital Motol, Prague, Czech Republic Host: Isabel Olivera Martinez, PhDLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.⁠⁠⁠Provide Feedback⁠⁠⁠Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: ⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠Facebook: ⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠LinkedIn: ⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠Email us: [email protected] to receive the EHA Educational Updates via ⁠⁠⁠https://eha.news/subscribe⁠⁠⁠ 

Get up to date with the latest EHA Clinical Practice Guidelines for Large B-cell lymphoma (LBCL) (⁠Large B‐cell lymphoma (LBCL): EHA Clinical Practice Guidelines for diagnosis, treatment, and follow‐up - Thieblemont - 2025 - HemaSphere - Wiley Online Library).⁠ Prof Catherine Thieblemont and Prof Marie José Kersten, two key authors of the guidelines,  walk us through the recommendations for Large B-cell lymphoma, covering diagnosis, treatment, and follow-up. Gain insights into key diagnostic considerations including staging, biopsy techniques and the importance of molecular testing. Our guests explain treatment strategies for first-line and relapse/refractory patient populations, highlighting the practice-changing introduction of CAR T therapy in second-line for eligible patients. Finally, they discuss the disparities of access to innovative treatments across Europe and explore future perspectives of LBCL management in Europe and beyond. Guests: Prof Catherine Thieblemont and Prof Marie José Kersten.  Professor Catherine Thieblemont from Saint-Louis Hospital in Paris. Professor Marie José Kersten from Amsterdam University Medical Centers (UMC) Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.⁠⁠⁠⁠⁠Provide Feedback⁠⁠⁠⁠⁠Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.⁠⁠⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠⁠⁠Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: ⁠⁠⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠⁠⁠Facebook: ⁠⁠⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠⁠⁠LinkedIn: ⁠⁠⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠⁠⁠Email us: [email protected] to receive the EHA Educational Updates via ⁠⁠⁠⁠⁠https://eha.news/subscribe⁠⁠⁠⁠⁠ 

In this episode of EHA Unplugged, patient advocate Peter Kapitein discusses the importance of connecting patients, researchers, and clinicians to accelerate cancer research and treatment. He shares insights from his work with Inspire2Live, focusing on collaboration, data ownership, affordability, and global access to innovative therapies. Guest: Peter KapiteinHost: Isabel Olivera Martinez, PhDLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.⁠⁠⁠⁠⁠⁠Provide Feedback⁠⁠⁠⁠⁠⁠Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.⁠⁠⁠⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠⁠⁠⁠Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: ⁠⁠⁠⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠⁠⁠⁠Facebook: ⁠⁠⁠⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠⁠⁠⁠LinkedIn: ⁠⁠⁠⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠⁠⁠⁠Email us: [email protected] to receive the EHA Educational Updates via ⁠⁠⁠⁠⁠⁠https://eha.news/subscribe⁠⁠⁠⁠⁠⁠ Guest: Peter KapiteinHost: Isabel Olivera Martinez, PhDLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.⁠⁠⁠⁠Provide Feedback⁠⁠⁠⁠Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.⁠⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠⁠Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: ⁠⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠⁠Facebook: ⁠⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠⁠LinkedIn: ⁠⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠⁠Email us: [email protected] to receive the EHA Educational Updates via ⁠⁠⁠⁠https://eha.news/subscribe⁠⁠⁠⁠ 

Get up to date with the latest ESMO-EHA guideline for Peripheral T- and natural killer-cell lymphomas (Peripheral T‐ and natural killer‐cell lymphomas: ESMO‐EHA Clinical Practice Guideline for diagnosis, treatment, and follow‐up - d'Amore - 2025 - HemaSphere - Wiley Online Library) Prof Francesco D'Amore (Aarhus University, Denmark) and Prof Massimo Federico (University of Modena and Reggio Emilia, Italy). In this episode, two key authors of the guidelines walk us through the recommendations for these rare, biologically diverse, and often aggressive- peripheral T cell and NK cell lymphomas. Our guests explain the conscious effort of the guidelines panel to provide evidence based detailed recommendations for each subtype of PTCLs to improve diagnosis, treatment, and follow up. The emphasis is on moving away from “one size fits all” DLBCL style approach toward entity- adapted strategies. Throughout the conversation, they stress the need to read the full guideline – including the supplementary material – and the importance of a multidisciplinary approach by experienced hematopathologists, ideally in expert or reference centres to give patients the best chance of appropriate, modern therapy.GuestS: Prof Francesco D'Amore and Prof Massimo Federico. Professor Francesco D'Amore is a Clinical Professor and Chair of the Department of Hematology at Aarhus University in Denmark Professor Massimo Federico is a Senior Professor of Medical Oncology at the University of Modena and Reggio Emilia in ItalyHost: Isabel Olivera Martinez, PhDLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.⁠⁠⁠Provide Feedback⁠⁠⁠Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: ⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠Facebook: ⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠LinkedIn: ⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠Email us: [email protected] to receive the EHA Educational Updates via ⁠⁠⁠https://eha.news/subscribe⁠⁠⁠